STOCK TITAN
  1. Home
  2. Sec-filings
  3. CVKD
  4. [Form 4] Cadrenal Therapeutics, Inc. Insider Trading Activity

Cadrenal Therapeutics (CVKD) CEO logs 652-share Rule 10b5-1 stock sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. CEO and Chairman Quang Pham reported small open-market sales of company common stock. He sold 303 shares on May 29, 2026 at a weighted average price of $5.01 per share and 349 shares on June 2, 2026 at a weighted average price of $4.46 per share, totaling 652 shares. The sales were executed under a pre-arranged Rule 10b5-1 trading arrangement. After these transactions, Pham holds 181,509 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power.

Positive

  • None.

Negative

  • None.
Insider Pham Quang X
Role CEO and Chairman
Sold 652 shs ($3K)
Type Security Shares Price Value
Sale Common Stock 349 $4.46 $2K
Sale Common Stock 303 $5.01 $2K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 181,509 shares (Direct, null); Common Stock — 200,000 shares (Indirect, The PVBQ Living Trust)
Footnotes (1)
  1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 through $5.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.40 through $4.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.
Shares sold May 29, 2026 303 shares at $5.01 Open-market sale, weighted average price within $5.00–$5.02 range
Shares sold June 2, 2026 349 shares at $4.46 Open-market sale, weighted average price within $4.40–$4.62 range
Total shares sold 652 shares Net open-market sales across two reported transactions
Direct holdings after transactions 181,509 shares Common stock directly owned by Quang Pham following sales
Indirect trust holdings 200,000 shares Common stock held via The PVBQ Living Trust
Rule 10b5-1 trading arrangement financial
"shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement"
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open market or private transaction financial
"Sale in open market or private transaction"
dispositive power financial
"has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pham Quang X
(Last)(First)(Middle)
C/O CADRENAL THERAPEUTICS, INC.
822 A1A NORTH, SUITE 306
(Street)
PONTE VEDRA FLORIDA 32082
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
CEO and Chairman
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/29/2026S303(1)D$5.01(2)181,858D
Common Stock06/02/2026S349(1)D$4.46(3)181,509D
Common Stock200,000IThe PVBQ Living Trust(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 through $5.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.40 through $4.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.
/s/ Quang X. Pham06/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Cadrenal Therapeutics (CVKD) report for Quang Pham?

Cadrenal Therapeutics reported that CEO and Chairman Quang Pham sold a total of 652 common shares in open-market transactions. These sales occurred on May 29, 2026 and June 2, 2026 and were executed under a pre-arranged Rule 10b5-1 trading plan.

At what prices did Quang Pham sell Cadrenal Therapeutics (CVKD) shares?

Quang Pham sold 303 shares at a weighted average price of $5.01 on May 29, 2026, within a $5.00–$5.02 range. He then sold 349 shares at a weighted average of $4.46 on June 2, 2026, within a $4.40–$4.62 range.

How many Cadrenal Therapeutics (CVKD) shares does Quang Pham hold after these sales?

After the reported transactions, Quang Pham directly holds 181,509 shares of Cadrenal Therapeutics common stock. He also indirectly holds 200,000 shares through The PVBQ Living Trust, where he has sole voting and dispositive power over the trust’s shares.

Were Quang Pham’s Cadrenal Therapeutics (CVKD) share sales pre-planned?

Yes. The filing states that the reported common stock sales by Quang Pham were made in accordance with a Rule 10b5-1 trading arrangement. This pre-arranged plan was adopted on September 25, 2025, allowing systematic sales independent of short-term market movements.

What does the weighted average price mean in the Cadrenal Therapeutics (CVKD) Form 4?

The filing explains that the reported sale prices are weighted average prices across multiple trades. Individual transactions occurred within stated price ranges, and Quang Pham has committed to provide detailed trade breakdowns to the issuer, shareholders, or SEC staff upon request.

How are indirect Cadrenal Therapeutics (CVKD) holdings reported for Quang Pham?

Quang Pham’s Form 4 shows 200,000 shares held indirectly through The PVBQ Living Trust. He is the trustee with sole voting and dispositive power, while his child is the sole beneficiary, so these shares are reported as his indirect beneficial ownership.